Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.

MRNA and MRK announced their personalized mRNA cancer vaccine combined with Keytruda passed its Phase 3 trial in melanoma, marking the first-ever Phase 3 success for both mRNA cancer therapy and individualized neoantigen therapy. Patients treated with the combination experienced longer recurrence-free periods and reduced cancer spread compared to Keytruda alone.

The two companies plan to present the trial findings to regulators, a step that precedes marketing approval applications. MRNA has built its platform on mRNA technology, previously validated in COVID-19 vaccines, while MRK's Keytruda is already one of the highest-grossing cancer drugs globally.

This milestone validates MRNA's broader oncology pipeline strategy beyond infectious disease and strengthens MRK's cancer franchise positioning. The personalized vaccine approach tailors treatment to each patient's tumor mutations, a differentiated mechanism from standard immunotherapies.

Both companies collaborated on the trial, sharing development costs and potential commercialization economics. The regulatory filing timeline will determine how quickly the treatment could reach the market and begin generating revenue.